Effects of Urotensin-Ⅱ antagonist on microvascular pathological changes in diabetic retinopathy

Xiangyu Ye,Yaohua Sheng,Changbin Qiu,Yulan Wang,Shuangshuang Ding
DOI: https://doi.org/10.3760/cma.j.issn.2095-0160.2006.02.013
2006-01-01
Abstract:Objective: Urotensin-II is a vasoactive peptide with stronger vasoconstrictive effectiveness. It may be involved in the pathogenesis of diabetic retinopathy. This paper was to assess the effects of Urotensin-II antagonist on microvascular pathological changes in diabetic retinopathy(DR). Methods: Animal models of DR were induced by injection of streptozocin in rats. Experimental rats were randomly divided into Sham + Veh (normal control, 11 rats), DM + Veh (diabetic model without treatment, 7 rats) and DM + 362 (diabetic model with Urotensin-II antagonist treatment, 20 rats) groups. Mean body weight and blood glucose levels of rats were recorded every 2 weeks during the experiment period and rats were scarified at the end of 6 months. Left eye of each rat was processed for elastase digest to determine retinal endothelial/pericyte cell ratios and the right eye were used for transmission electron microscopy examination to detect basement membrane thickness. Results: Blood glucose level was significantly higher in the DM + Veh group and DM + 362 group than the Sham + Veh group 2 weeks after diabetes was induced, and that of DM +362 group was considerably lower in comparison with DM + Veh group after 4 weeks. There was no apparent difference in mean body weight between DM + Veh group and DM + 362 group (P > 0.05). Endothelial cell/pericyte ratios and basement membrane thickness were significantly increased in the DM + 362 rats compared with Sham + Veh rats(1.60 ± 0.01 versus 1.19 ± 0.01 in E/P ratios, P < 0.01 and 106.40 ± 18.65 nm versus 83.36 ± 14.46 nm in basement membrane thickness, P < 0.01) and significantly reduced in comparison with DM + Veh rats (2.10 ± 0.07 in E/P ratios, P < 0.01 and 116.91 ± 17.65 nm in basement membrane thickness, P < 0.01). ConclusionL: Urotensin-II antagonist may be useful in prevention from the early pathological changes of DR.
What problem does this paper attempt to address?